問卷

TPIDB > Search Result

Search Result

篩選

List

35Cases

2024-01-01 - 2027-02-28

Phase II/III

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Not yet recruiting2Sites

Recruiting4Sites

2021-01-04 - 2026-03-31

Others

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Recruiting6Sites

2021-07-27 - 2026-09-30

Phase II

Active
xxxxxx
  • Condition/Disease

    xxxxxx

  • Test Drug

    xxxxxx

Participate Sites
13Sites

Recruiting13Sites

2024-08-01 - 2026-12-31

Phase II

Active
xxxxxx
  • Condition/Disease

    xxxxxx

  • Test Drug

    xxxxxx

Participate Sites
5Sites

Recruiting5Sites

2024-07-17 - 2026-06-30

Phase II

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Recruiting5Sites

2024-07-01 - 2027-11-28

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
8Sites

Recruiting8Sites

2025-06-16 - 2029-09-30

Phase III

Active
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITYR Study)
  • Condition/Disease

    Bronchiectasis

  • Test Drug

    BI 1291583 or matching placebo

Participate Sites
6Sites

Recruiting6Sites

2023-10-02 - 2028-01-05

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
10Sites

Recruiting10Sites

2023-10-16 - 2027-09-09

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
9Sites

Recruiting9Sites

2021-05-01 - 2023-10-30

Phase II

A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 2 Study of the Efficacy and the Safety and Tolerability of BMS-986278 in Participants With Pulmonary Fibrosis
  • Condition/Disease

    Pulmonary Fibrosis

  • Test Drug

    BMS-986278

Participate Sites
3Sites

Recruiting3Sites

1 2 3 4